Moderate to Severe Psoriatic Arthritis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Moderate to Severe Psoriatic Arthritis Emerging Therapy and TPP Insights

Thelansis’s “Moderate to Severe Psoriatic Arthritis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Moderate to Severe Psoriatic Arthritis Overview

Moderate to severe psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis that can affect peripheral joints, entheses, the spine, and nails. Symptoms may include joint pain and swelling, dactylitis, stiffness, fatigue, and reduced mobility; untreated inflammation can cause structural damage. Treatment is tailored to the affected domains, disease activity, skin involvement, comorbidities, and prior response. Options include conventional DMARDs such as methotrexate for peripheral arthritis, biologics targeting TNF, IL-17, IL-23 or IL-12/23, and selected oral agents such as JAK or PDE4 inhibitors. Choice matters: coexisting inflammatory bowel disease or uveitis can favor some biologics over others. Although targeted therapies have improved disease control, some patients have incomplete response or lose benefit over time. Ongoing care uses a treat-to-target approach to limit inflammation, preserve function, and improve quality of life.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)